Literature DB >> 11335904

Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube?

T M Mekhail1, D J Adelstein, L A Rybicki, M A Larto, J P Saxton, P Lavertu.   

Abstract

BACKGROUND: Multimodality treatments for patients with squamous cell head and neck carcinoma often produce significant mucositis and dysphagia, mandating enteral nutritional support. Patient preference has resulted in the increasing use of percutaneous endoscopic gastrostomy (PEG) tubes rather than nasogastric (NG) tubes. Anecdotal observations of prolonged PEG dependence and of a need for pharyngoesophageal dilatation in PEG patients prompted a retrospective review of the use of both types of feeding tubes.
METHODS: Patients who were treated on clinical trials of radiotherapy or chemoradiotherapy for squamous cell head and neck carcinoma between 1989 and 1997 were reviewed retrospectively. Data were gathered regarding demographics, primary tumor site, T and N classifications, and the need for feeding tube placement. In patients requiring feeding tubes, the type and duration of the feeding tube, the need for tracheostomy, the need for pharyngoesophageal dilatation, and the degree of mucositis and dysphagia at baseline and at 1 month, 3 months, 6 months, and 12 months after beginning treatment were recorded. Comparisons were then made between the NG and the PEG groups.
RESULTS: Ninety-one feeding tubes were placed in 158 patients over the 8-year interval. A hypopharyngeal primary site, female gender, a T4 primary tumor, and treatment with chemoradiotherapy were predictive of a need for feeding tube placement. NG tubes were placed in 29 patients, and PEG tubes were placed in 62 patients. PEG patients had more dysphagia at 3 months (59% vs. 30%, respectively; P = 0.015) and at 6 months (30% vs. 8%, respectively; P = 0.029) than NG patients. The median tube duration was 28 weeks for PEG patients compared with 8 weeks for NG patients, (P < 0.001). Twenty-three percent of PEG patients needed pharyngoesophageal dilatation compared with 4% of NG patients (P = 0.022). These end points could not be correlated with age, stage, primary tumor site, or tracheostomy placement.
CONCLUSIONS: Although patients treated for head and neck carcinoma find that the PEG tube is a more acceptable route for enteral nutrition than the NG tube, in the authors' experience, a PEG tube was required for longer periods of time and was associated with more persistent dysphagia and an increased need for pharyngoesophageal dilatation. A randomized prospective trial is needed to test these observations. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11335904

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  76 in total

Review 1.  [Enteral feeding tubes for critically ill patients].

Authors:  J Braun; T Bein; C H R Wiese; B M Graf; Y A Zausig
Journal:  Anaesthesist       Date:  2011-04       Impact factor: 1.041

Review 2.  Esophageal and pharyngeal strictures: report on 1,862 endoscopic dilatations using the Savary-Gilliard technique.

Authors:  Elsa Piotet; Anette Escher; Philippe Monnier
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-09-26       Impact factor: 2.503

3.  Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment.

Authors:  Giorgio Capuano; Pier Carlo Gentile; Federico Bianciardi; Michela Tosti; Anna Palladino; Mario Di Palma
Journal:  Support Care Cancer       Date:  2009-06-29       Impact factor: 3.603

4.  The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy.

Authors:  Beste M Atasoy; Oya Yonal; Birsen Demirel; Faysal Dane; Yusuf Yilmaz; Cem Kalayci; Ufuk Abacioglu; Nese Imeryuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-07       Impact factor: 2.503

5.  Factors affecting the success of endoscopic bougia dilatation of radiation-induced esophageal stricture.

Authors:  Yaşar Tuna; Erdem Koçak; Dinç Dinçer; Seyfettin Köklü
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

6.  Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis.

Authors:  Beth M Beadle; Kai-Ping Liao; Sharon H Giordano; Adam S Garden; Katherine A Hutcheson; Stephen Y Lai; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2016-09-23       Impact factor: 6.860

7.  Feeding Tube Utilization in Patients with Salivary Gland Malignancies.

Authors:  Diane Wenhua Chen; Jan S Lewin; Li Xu; Stephen Y Lai; G Brandon Gunn; Clifton David Fuller; Abdallah S R Mohamed; Aasheesh Kanwar; Erich M Sturgis; Katherine A Hutcheson
Journal:  Otolaryngol Head Neck Surg       Date:  2016-10-03       Impact factor: 3.497

8.  Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score--report from a single U.K. institution.

Authors:  Charlotte J Ingle; Kent Yip; Valerie Caskie; Catherine Dyson; Amanda Ford; Christopher D Scrase
Journal:  Head Neck Oncol       Date:  2010-10-14

Review 9.  Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy.

Authors:  Brenda Nugent; Sian Lewis; Joe M O'Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

10.  Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy.

Authors:  Baoqing Li; Dan Li; Derick H Lau; D Gregory Farwell; Quang Luu; David M Rocke; Kathleen Newman; Jean Courquin; James A Purdy; Allen M Chen
Journal:  Radiat Oncol       Date:  2009-11-12       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.